ASND Stock Risk & Deep Value Analysis
Ascendis Pharma A/S
DVR Score
out of 10
What You Need to Know About ASND Stock
We analyzed Ascendis Pharma A/S using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ASND through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
ASND Risk Analysis & Red Flags
What Could Go Wrong
The rapid commercial ramp-up of YORVIPATH (€196.9M in Q1 2026) and SKYTROFA (€44.0M in Q1 2026) could decelerate unexpectedly due to unforeseen competitive pressures, payer access challenges, or slower-than-anticipated patient uptake, jeopardizing the company's path to sustained and significant operating profitability and free cash flow generation.
Risk Matrix
Overall
Moderate
Financial
Medium
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
Medium
Red Flags
- ⚠
High P/S (TTM) multiple of ~37.5x indicates that significant future growth and pipeline success are already priced into the stock, leaving limited margin for error if commercial execution falters.
- ⚠
Institutional ownership saw a -17.17% quarter-over-quarter change (total 66,622,814 shares held), which, while potentially rebalancing, warrants monitoring for sustained institutional outflows.
- ⚠
While improving, total financial liabilities of €1.28 billion (as of Q1 2026) still represent a considerable debt load relative to cash of €572.8 million, even after convertible note redemption.
Upcoming Risk Events
- 📅
Q2 2026 Earnings Miss (August 7, 2026): Revenue for YORVIPATH or SKYTROFA falls significantly below consensus estimates, or operating profit turns negative, challenging the commercial ramp-up thesis.
- 📅
Negative TransCon CNP Phase 3 Readout (late 2026 - early 2027): Failure of TransCon CNP to meet primary endpoints in its pivotal trial would reduce pipeline value and impact future growth expectations significantly.
When to Reconsider
- 🚪
Exit if quarterly YORVIPATH or SKYTROFA revenue growth decelerates below 50% year-over-year for two consecutive quarters, indicating a loss of commercial momentum.
- 🚪
Sell if the company reports two consecutive quarters of negative operating profit, signaling a deviation from the recent shift to profitability and potential cash burn concerns.
- 🚪
A confirmed failure or significant delay in the TransCon CNP Phase 3 clinical trial could warrant an exit due to substantial pipeline de-risking.
Unlock ASND Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
If Ascendis Pharma successfully executes the continued rapid commercial expansion of YORVIPATH and SKYTROFA, driving combined annual sales to over $2 billion by FY2028, and simultaneously achieves positive Phase 3 results and subsequent regulatory approval for TransCon CNP, then the company's operating profitability and free cash flow generation will solidify, potentially leading to a market capitalization exceeding $40 billion (a 3x+ return from current levels) as the TransCon platform is established as a leading, multi-product engine in high-value rare disease markets. This is bullish because the market may currently underestimate the peak sales potential of its commercial portfolio and the broad applicability of the TransCon technology across its pipeline.
Is ASND Stock Undervalued?
Unlock the full AI analysis for ASND
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
ASND Price Targets & Strategy
12-Month Target
$340.50
Bull Case
$400.00
Bear Case
$180.00
Valuation Basis
Based on 15x forward P/S applied to projected FY2027 revenue of $1.5B (assuming continued strong commercial ramp-up and pipeline progression).
Entry Strategy
Consider dollar-cost averaging on dips towards the $200-$210 range, which could act as a psychological support level following recent strong performance. Monitor for consolidation post-Q1 earnings pop.
Exit Strategy
Take partial profits at $340-$350. Set a stop-loss at $190 to protect capital against significant market or company-specific setbacks.
Portfolio Allocation
6% for moderate-to-aggressive risk tolerance, reflecting high growth potential balanced with competitive and execution risks in the biotech sector.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is ASND Financially Healthy?
Valuation
P/E Ratio
25.65
Forward P/E
52.01
Price/Book
25.81
Price/Sales
21.68
Profitability
Gross Margin
89.04%
Operating Margin
-0.84%
Net Margin
57.28%
Return on Equity
128.97%
Revenue Growth
134.82%
EPS
$7.59
Balance Sheet
Current Ratio
1.04
Quick Ratio
0.72
Debt/Equity
1.93
Total Debt
$930.75M
Cash & Equivalents
$580.21M
Cash Flow
Operating Cash Flow
-$193.73M
Free Cash Flow
-$198.73M
Other
Beta (Volatility)
0.40
Does ASND Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The TransCon platform creates a durable competitive advantage by enabling the development of long-acting, potentially superior versions of therapeutic proteins and peptides. This proprietary technology is difficult for competitors to replicate and provides a competitive edge in targeted rare disease markets where patient convenience and consistent therapeutic levels are critical. Its durability is reinforced by ongoing pipeline development leveraging the same platform.
Moat Erosion Risks
- •Emergence of novel drug delivery technologies or gene therapies that offer superior profiles or completely bypass the need for existing protein/peptide therapies, negating the TransCon advantage.
- •Patent expirations on the core TransCon technology or individual approved products in the long term (beyond 10 years), allowing generic competition to erode market share.
ASND Competitive Moat Analysis
Sign up to see competitive advantages
ASND Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral (no specific data, but overall positive market sentiment from recent earnings beat likely outweighs any transient social media noise)
Institutional Sentiment
Positive (Analyst consensus 'Moderate Buy / Buy', with recent upgrades from Citigroup and Wall Street Zen, but institutional ownership saw a -17.17% QoQ change in holdings).
Insider Activity (Form 4)
No specific Form 4 insider transactions were retrieved in the last 90 days. Institutional ownership saw a -17.17% quarter-over-quarter change in holdings.
Options Flow
Normal options activity (no specific unusual options activity data available in the retrieved sources).
Earnings Intelligence
Next Earnings
2026-08-07 (Estimated for Q2 2026)
Surprise Probability
Medium-High (given the significant Q1 2026 revenue beat and recent analyst upgrades, suggesting positive momentum for commercial products).
Historical Earnings Pattern
Likely positive reaction given recent Q1 2026 revenue beat and analyst upgrades. The stock is prone to significant moves based on commercial performance and pipeline updates typical for biotech companies.
Key Metrics to Watch
Competitive Position
Top Competitor
BMRN (BioMarin Pharmaceutical Inc.)
Market Share Trend
Gaining (demonstrated by +144.2% YoY revenue growth, largely driven by increasing market penetration of YORVIPATH and SKYTROFA in their respective rare disease markets).
Valuation vs Peers
Trading at a premium to many rare disease peers on P/S (TTM) (approx. 37.5x) due to its proprietary TransCon platform and strong growth trajectory, reflecting high investor expectations for pipeline expansion and future profitability.
Competitive Advantages
- •Proprietary TransCon platform technology allows for the creation of best-in-class, long-acting therapeutic peptides and proteins with improved efficacy and convenience profiles.
- •Established commercial infrastructure and market access in high-value rare endocrine disease segments.
- •Strong intellectual property protection around its platform and approved products.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive ASND Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 Earnings Report (August 7, 2026): Continued strong revenue growth for YORVIPATH and SKYTROFA, and sustained operating profitability above €30 million would re-affirm commercial strength.
- •Positive analyst coverage & target price increases (Q2 2026-Q3 2026): Further upgrades from institutions following Q1 beat and strategic de-risking could drive additional institutional interest and stock re-rating.
Medium-Term (6-18 months)
- •TransCon CNP Phase 3 Clinical Trial Readout (late 2026 - early 2027): Positive results for TransCon CNP (achieving primary endpoints) in achondroplasia could open up a new multi-billion dollar market opportunity for the TransCon platform.
- •Regulatory Approval for TransCon CNP (2027-2028): FDA/EMA approval for TransCon CNP, leading to a new product launch and diversified revenue streams beyond YORVIPATH and SKYTROFA, potentially adding $500M+ to annual revenue within 2 years of launch.
Long-Term (18+ months)
- •Expansion of TransCon Platform to New Indications (2028-2030): Successful development and commercialization of additional TransCon pipeline candidates, including combination therapies (e.g., TransCon CNP + TransCon hGH), expanding the platform's total addressable market to over $10B annually.
- •Strategic Partnerships or Acquisition Interest (2028-2031): The proven success and broad applicability of the TransCon platform could attract significant strategic partnerships or make Ascendis an attractive acquisition target for a large pharmaceutical company, potentially yielding a valuation multiple above 5x current market cap.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for ASND?
- ✓
Watch for quarterly YORVIPATH and SKYTROFA revenue growth rates to consistently exceed analyst consensus, indicating stronger-than-expected market penetration.
- ✓
Monitor the progression of TransCon CNP through regulatory milestones (Phase 3 readout, NDA/BLA submission, approval) for validation of pipeline strength.
- ✓
Observe operating profit margins; sustained expansion indicates successful scaling and cost control, crucial for long-term value creation.
Bull Case Analysis
Sign up free to see the bull case
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Ascendis Pharma A/S Makes Money
Ascendis Pharma A/S is a global biopharmaceutical company specializing in the development of innovative therapeutics for rare endocrine diseases. Its business model centers on the proprietary TransCon (Transient Conjugation) technology platform, which intelligently creates long-acting versions of established or novel compounds to improve treatment efficacy, safety, and patient adherence. The company generates revenue primarily through the commercialization of its approved products, such as SKYTROFA for pediatric growth hormone deficiency and YORVIPATH for adult hypoparathyroidism, targeting high-value, specialized markets where its differentiated products command strong pricing and demand.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Ascendis Pharma A/S (ASND)?
As of May 29, 2026, Ascendis Pharma A/S has a DVR Score of 9.2 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Ascendis Pharma A/S?
Ascendis Pharma A/S's market capitalization is approximately $14.8B..
What is the risk level for ASND stock?
Our analysis rates Ascendis Pharma A/S's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of ASND?
Ascendis Pharma A/S currently has a price-to-earnings (P/E) ratio of 25.7. This is in line with broader market averages.
Is Ascendis Pharma A/S's revenue growing?
Ascendis Pharma A/S has reported revenue growth of 134.8%. The company is showing strong top-line momentum.
Is ASND stock profitable?
Ascendis Pharma A/S has a profit margin of 57.3%. This indicates strong profitability.
How often is the ASND DVR analysis updated?
Our AI-powered analysis of Ascendis Pharma A/S is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 29, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ASND (Ascendis Pharma A/S) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.